Literature DB >> 23466699

PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Cornelia Ringer1, Luisa-Sybille Büning, Martin K H Schäfer, Lee E Eiden, Eberhard Weihe, Burkhard Schütz.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic peptide with autocrine neuroprotective and paracrine anti-inflammatory properties in various models of acute neuronal damage and neurodegenerative diseases. Therefore, we examined a possible beneficial role of endogenous PACAP in the superoxide dismutase 1, SOD1(G93A), mouse model of amyotrophic lateral sclerosis (ALS), a lethal neurodegenerative disease particularly affecting somatomotor neurons. In wild-type mice, somatomotor and visceromotor neurons in brain stem and spinal cord were found to express the PACAP specific receptor PAC1, but only visceromotor neurons expressed PACAP as a potential autocrine source of regulation of these receptors. In SOD1(G93A) mice, only a small subset of the surviving somatomotor neurons showed induction of PACAP mRNA, and somatomotor neuron degeneration was unchanged in PACAP-deficient SOD1(G93A) mice. Pre-ganglionic sympathetic visceromotor neurons were found to be resistant in SOD1(G93A) mice, while pre-ganglionic parasympathetic neurons degenerated during ALS disease progression in this mouse model. PACAP-deficient SOD1(G93A) mice showed even greater pre-ganglionic parasympathetic neuron loss compared to SOD1(G93A) mice, and additional degeneration of pre-ganglionic sympathetic neurons. Thus, constitutive expression of PACAP and PAC1 may confer neuroprotection to central visceromotor neurons in SOD1(G93A) mice via autocrine pathways. Regarding the progression of neuroinflammation, the switch from amoeboid to hypertrophic microglial phenotype observed in SOD1(G93A) mice was absent in PACAP-deficient SOD1(G93A) mice. Thus, endogenous PACAP may promote microglial cytodestructive functions thought to drive ALS disease progression. This hypothesis was consistent with prolongation of life expectancy and preserved tongue motor function in PACAP-deficient SOD1(G93A) mice, compared to SOD1(G93A) mice. Given the protective role of PACAP expression in visceromotor neurons and the opposing effect on microglial function in SOD1(G93A) mice, both PACAP agonism and antagonism may be promising therapeutic tools for ALS treatment, if stage of disease progression and targeting the specific auto- and paracrine signaling pathways are carefully considered.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466699      PMCID: PMC3955759          DOI: 10.1016/j.nbd.2013.02.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  73 in total

1.  Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes.

Authors:  M Grimaldi; S Cavallaro
Journal:  Eur J Neurosci       Date:  1999-08       Impact factor: 3.386

2.  The effect of pituitary adenylate cyclase activating peptide (PACAP) on the nociceptive formalin test.

Authors:  Y Zhang; A B Malmberg; B Sjölund; T L Yaksh
Journal:  Neurosci Lett       Date:  1996-04-05       Impact factor: 3.046

3.  Oculomotor nuclear pathology in amyotrophic lateral sclerosis.

Authors:  K Okamoto; S Hirai; M Amari; T Iizuka; M Watanabe; N Murakami; M Takatama
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1.

Authors:  J Kong; Z Xu
Journal:  J Neurosci       Date:  1998-05-01       Impact factor: 6.167

5.  The effects of axotomy and preganglionic denervation on the expression of pituitary adenylate cyclase activating peptide (PACAP), galanin and PACAP type 1 receptors in the rat superior cervical ganglion.

Authors:  K Moller; M Reimer; E Ekblad; J Hannibal; J Fahrenkrug; M Kanje; F Sundler
Journal:  Brain Res       Date:  1997-11-14       Impact factor: 3.252

6.  Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus.

Authors:  X Zhou; W I Rodriguez; R A Casillas; V Ma; J Tam; Z Hu; V Lelievre; A Chao; J A Waschek
Journal:  J Neurosci Res       Date:  1999-09-15       Impact factor: 4.164

7.  Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats.

Authors:  Dóra Reglodi; Andrea Tamás; Andrea Lubics; Luca Szalontay; István Lengvári
Journal:  Regul Pept       Date:  2004-12-15

8.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

Authors:  M E Gurney; H Pu; A Y Chiu; M C Dal Canto; C Y Polchow; D D Alexander; J Caliendo; A Hentati; Y W Kwon; H X Deng
Journal:  Science       Date:  1994-06-17       Impact factor: 47.728

9.  Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes.

Authors:  A Arimura; A Somogyvári-Vigh; A Miyata; K Mizuno; D H Coy; C Kitada
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

10.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

View more
  7 in total

1.  Disruption of calcitonin gene-related peptide signaling accelerates muscle denervation and dampens cytotoxic neuroinflammation in SOD1 mutant mice.

Authors:  Cornelia Ringer; Sarah Tune; Mirjam A Bertoune; Hans Schwarzbach; Kazutake Tsujikawa; Eberhard Weihe; Burkhard Schütz
Journal:  Cell Mol Life Sci       Date:  2016-08-23       Impact factor: 9.261

2.  Pituitary adenylate cyclase-activating polypeptide (PACAP) contributes to the proliferation of hematopoietic progenitor cells in murine bone marrow via PACAP-specific receptor.

Authors:  Zhifang Xu; Hirokazu Ohtaki; Jun Watanabe; Kazuyuki Miyamoto; Norimitsu Murai; Shun Sasaki; Minako Matsumoto; Hitoshi Hashimoto; Yutaka Hiraizumi; Satoshi Numazawa; Seiji Shioda
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

3.  Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Pilar Rojas; Ana I Ramírez; Manuel Cadena; José A Fernández-Albarral; Elena Salobrar-García; Inés López-Cuenca; Irene Santos-García; Eva de Lago; José L Urcelay-Segura; José M Ramírez; Rosa de Hoz; Juan J Salazar
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

4.  PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy.

Authors:  Shanshan Li; Jin Huang; Yi Guo; Jiaqi Wang; Shanshan Lu; Bin Wang; Yinan Gong; Siru Qin; Suhong Zhao; Shenjun Wang; Yangyang Liu; Yuxin Fang; Yongming Guo; Zhifang Xu; Luis Ulloa
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

5.  PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells.

Authors:  Jocelyn Karunia; Aram Niaz; Mawj Mandwie; Sarah Thomas Broome; Kevin A Keay; James A Waschek; Ghaith Al-Badri; Alessandro Castorina
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

6.  Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis.

Authors:  Stephen R Pfohl; Martin T Halicek; Cassie S Mitchell
Journal:  J Neuromuscul Dis       Date:  2015-06-04

7.  PACAP Modulates the Autophagy Process in an In Vitro Model of Amyotrophic Lateral Sclerosis.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Salvatore Saccone; Concetta Federico; Sebastiano Cavallaro; Dora Reglodi; Velia D'Agata
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.